A randomized, double-blind Phase 1 Safety, Pharmacokinetic and Pharmacodynamic clinical trial of SRK-015 in Healthy Volunteers
Latest Information Update: 13 May 2021
Price :
$35 *
At a glance
- Drugs Apitegromab (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; First in man
- Sponsors Scholar Rock
- 11 May 2021 Results published in the peer-reviewed journal Advances in Therapy.
- 11 May 2021 Results published in Scholar Rock Media Release
- 08 May 2021 Results published in the Advances in Therapy